上海勝普澤泰醫(yī)藥科技有限公司致力于創(chuàng)新型、難成藥、前瞻性靶點的多肽創(chuàng)新藥研發(fā)，利用20年真實數(shù)據(jù)積累的新藥發(fā)現(xiàn)平臺“Chemical Space”，以人工智能和藥物結(jié)構(gòu)大數(shù)據(jù)為驅(qū)動，為全球制藥企業(yè)提供一站式多肽創(chuàng)新藥研發(fā)服務(wù)。

公司在全球各地設(shè)立5個模塊中心。總部在上海，AI與新藥發(fā)現(xiàn)中心在瑞士巴塞爾，化學(xué)合成中試基地在福建漳州，臨床前研究基地在福建廈門以及位于江蘇泰興的大型多肽API生產(chǎn)基地。

公司通過以虛擬篩選與濕實驗結(jié)合的方式，按照客戶指標(biāo)交付經(jīng)細胞、動物實驗等驗證的創(chuàng)新藥專利分子，并為客戶開發(fā)新藥分子的生產(chǎn)工藝以及生產(chǎn)用于臨床、商業(yè)化的原料藥。

Space Peptides is committed to R&D of innovative peptide drugs with innovative, difficult to produce drugs and forward-looking targets，by utilizing "Chemical Space", a new drug discovery platform based on accumulation of 20 years’ real data, is driven by artificial intelligence and big data on drug structure to provide one-stop drug R&D services for global pharmaceutical companies.

The company has set up five module centers around the world. The headquarters is in Shanghai, the AI and New Drug Discovery Center is in Basel, Switzerland, the pilot chemical synthesis base is in Zhangzhou, Fujian, the preclinical research base is in Xiamen, Fujian, and the peptide API production base is in Taixing, Jiangsu. 

By combining virtual screening with wet experiments, Space Peptides deliver innovative drug patent molecules verified by cell and animal experiments according to customer indexes, and develop the production process of new drug molecules for customers as well as the production of API for clinical and commercial use.